Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg) for the treatment of retinal diseases, including neovascular (wet) age-related macular degeneration (nAMD)
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg) for the treatment of retinal diseases, including neovascular (wet) age-related macular degeneration (nAMD).
The top three firms on F4's Biotech & Life Sciences investor list.